Phaseline

Targets › MGMT

MGMT (Methylated-DNA--protein-cysteine methyltransferase): drug programs, companies and trials

9 programs from 8 companies in 10 trials: 4 Phase 2, 3 Phase 3, 3 Phase 1; Oncology; next expected readout Dec 2026.

Involved in the cellular defense against the biological effects of O6-methylguanine (O6-MeG) and O4-methylthymine (O4-MeT) in DNA. Repairs the methylated nucleobase in DNA by stoichiometrically transferring the methyl group to a cysteine residue in the enzyme. This is a suicide reaction: the enzyme is irreversibly inactivated. (UniProt, P16455)

Open in Phaseline: the race on MGMT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Centre Oscar LambretTemozolomide (TMZ)
Alkylating agent; DNA methylating agent that induces O6-methylguanine lesions
MGMTPhase 3GlioblastomaJun 2027
Alliance for Clinical Trials in OncologyConcomitant temozolomide (TMZ)
Alkylating agent; DNA methylating chemotherapy
MGMTPhase 3Brain and Central Nervous System TumorsOct 2029
Leland MethenyO6-benzylguanine
Purine analog that selectively and irreversibly inactivates O6-alkylguanine DNA-alkyltrans
MGMTPhase 2Glioblastoma MultiformeMar 2027
Leland MethenyP140K-MGMT
Ex vivo cultured CD34+ hematopoietic stem cells transduced with P140K MGMT gene to confer
MGMTPhase 2Glioblastoma MultiformeMar 2027
Sunnybrook Health Sciences CentreDose escalation + Reduced Margin Adaptive Radiotherapy on MR-Linac with concurre
Hypofractionated radiotherapy with simultaneous integrated boost (SIB) delivered via MR-gu
MGMTPhase 2Glioblastoma Multiforme, AdultDec 2027
AHS Cancer Control AlbertaTemozolomide
DNA alkylating agent; induces DNA damage leading to cell death
MGMTPhase 2Glioblastoma MultiformeJun 2032
John FlickingerTemozolomide
Alkylating agent; methylates DNA at N-7 guanine and N-3 adenine positions
MGMTPhase 1GlioblastomaDec 2026
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoTemozolomide
Alkylating agent; DNA methylating agent with activity in MGMT-methylated tumors
MGMTPhase 1Metastatic Colorectal CancerJan 2027
Neonc TechnologiesNEO212
Covalent conjugate of temozolomide and perillyl alcohol (POH-TMZ)
MGMTPhase 1Diffuse Astrocytoma, IDH-MutantFeb 2027

Conditions

Glioblastoma Multiforme (3) Brain and Central Nervous System Tumors (2) Glioblastoma (2) Glioblastoma Multiforme, Adult (1) Diffuse Astrocytoma, IDH-Mutant (1) Metastatic Colorectal Cancer (1)

Modalities

small molecule (4), mixed (4)

Companies

Leland Metheny (2) Alliance for Clinical Trials in Oncology (1) Sunnybrook Health Sciences Centre (1) AHS Cancer Control Alberta (1) Neonc Technologies (1) Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) John Flickinger (1) Centre Oscar Lambret (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.